We are truly honoured to share that AstraZeneca was named Company of the Year at the 2020 Scrip Awards- an annual award which celebrates the essential role that the pharmaceutical, biotech and other allied industries play in improving healthcare. The award, which covered the year to 31 May 2020, recognises our achievements in a number of areas across the Company, including exceptional pipeline delivery, the continued transformation of our portfolio and our industry-leading sales growth across regions and main therapy areas, as well as exceptional growth in China and Emerging Markets.
We are honoured to be recognised with this award, made possible by our employees’ tireless commitment to pushing the boundaries of science to deliver life-changing medicines. Despite the COVID-19 pandemic, they remained focused, maintained momentum and demonstrated a high degree of resilience. I have no doubt this recognition will energise and motivate all of us to achieve even more.
Scrip also recognized our commitment to being a great place to work while contributing to society and the planet via initiatives such as Ambition Zero Carbon. Lastly, Scrip noted the way our people lived their purpose and values during the first few months of the COVID-19 pandemic by providing emergency relief, ensuring continuity of patient care, and protecting its staff and critical operations while contributing its science through research and development of treatments to combat the virus.
In addition to the Company of the Year accolade, our teams won additional awards for:
The China Biopharma Leadership Award: AstraZeneca China
During the period covered by the award, we added four medicines to the China portfolio and completed six strategic partnerships across multiple therapy areas. We also opened the Wuxi International Life Science Innovation Campus in collaboration with the local government and supported initiatives to overcome the COVID-19 pandemic and keep serving patients.
Best Partnership Alliance Award: Amgen, AstraZeneca, GSK and Janssen for the UK Biobank Whole Genome Sequencing Project
We joined a consortium of peer companies, supported by the UK government and the Wellcome Trust, to undertake the world’s largest genetics project, aimed at completing the whole genome sequencing of 500,000 participant samples stored within the UK Biobank.
Throughout 2020, we made great progress across our three strategic priorities: delivering growth, accelerating our science and being a great place to work. It was a year focused on realising the potential of our pipeline across cardiovascular, renal and metabolism, oncology, respiratory and immunology- bringing medicines to patients as quickly as possible.
As we look towards next year, COVID-19 will demand continued collaboration from the scientific community, industry, governments and every single person around the globe. We remain hopeful with the introduction of new vaccines, therapeutics and public health measures, we will not only defeat this virus together, but also advance new medicines for patients facing high unmet needs.